High frequency spinal cord stimulation for chronic back and leg pain

Interdisciplinary Neurosurgery

Maria Paula Arce-Martinez¹  Hernan Felipe Guillen-Burgos²  Salvador Mattar³  Yeiris Miranda-Acosta⁴  Dieb Maloof⁵  Jibril-Osman Farah⁵  Nicolás Samprón⁶  Sergio Torres-Bayona⁷ 

[1] Centro de Investigaciones Clínicas y Traslacional, La Misericordia Clínica Internacional. Universidad Simón Bolívar, Barranquilla 080002, Colombia;Corresponding author at: Los Cobos Medical Center, Cra 9131a-40, Bogotá 110111, Colombia.;Department of Neurological Surgery and Spine Unit, Los Cobos Medical Center, Bogotá 110111, Colombia;Universidad del Bosque, Bogotá 110111, Colombia;Centro de Investigaciones Clínicas y Traslacional, La Misericordia Clínica Internacional. Universidad Simón Bolívar, Barranquilla 080002, Colombia;Department of Neurological Surgery and Spine Unit, Los Cobos Medical Center, Bogotá 110111, Colombia;Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Ln, Liverpool L9 7LJ, United Kingdom;

关键词: Spinal cord stimulation;    High frequency stimulation;    Chronic back pain;    Chronic neuropathic pain;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: High frequency stimulation (HFS) may provide pain relief without the paresthesias typical of traditional low-frequency Spinal cord stimulation (SCS). Methods: A consecutive single-center series of patients was retrospectively reviewed to evaluate safety and efficacy of HF10 therapy. In this 24-month study, 62 patients with variables pathologies (44 patients with back failure surgery syndrome (FBSS), 18 patients with chronic peripheral neuropathic pain in the lower limbs (NeppL) were included to be treated with HF10. Pain outcomes were compared from preoperative baseline and at the conclusion of each study period. Clinical features, outcomes and complications were reviewed. Results: 62 patients completed this study. All patients had a successful trial before the definitive implantation of a spinal cord stimulator at the low dorsal level. The mean follow-up period was 11 months, ranging from 6 to 24 months. 6 patients showed no change from baseline visual analogue scale (VAS) after permanent implant and 2 had improved during the trial but was aggravated after the permanent implant placement. At 1 month, 63% of implanted HF10 therapy subjects were responders and 77% at 6 months. The average baseline, trial and postoperative Visual Analogue Scale (VAS) was 8.1, 3.6 and 4.2 respectively. When compared to the baseline, the average reduction achieved during the VAS trial was 4.5 points, accounting for a 56% pain reduction. The long-term failure rate was 22%. Conclusions: This study generated preliminary evidence showing improved VAS current pain scores in absence of paresthesias and increase patient satisfaction with HF10 spinal cord stimulation.

【 授权许可】

Unknown